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Melatonin is one of the most versatile and ubiquitous molecule widely distributed in na-
ture has been reported to play a role in a wide variety of physiological responses including
reproduction, circadian homeostasis, sleep, retinal neuromodulation, and vasomotor re-
sponses. In most vertebrates, including humans, melatonin is synthesized primarily in the
pineal gland and is regulated by the environmental light ⁄ dark cycle via the suprachias-
matic nucleus. Melatonin is synthesized in all areas of the body such as gastrointestinal
tract, skin, bone marrow, retina and in lymphocytes, from which it may influence other
physiological functions through paracrine signalling. In addition to regulation of circadian
rhythm of melatonin a variety of other physiological effects such as hypnotic, antide-
pressant, antiepileptic, oncostatic, immunomodulatory, antiosteoporotic, in cardiovascu-
lar disease, neuromodulatory and cerebral ischaemic condition have been reported.
Moreover there is scarcity of literature that reviewed the scientific evidence for its use in
these conditions. Therefore in this article we review recent advances in this research field,
which is preceded by a concise account of general information about melatonin, melatonin
receptors and intracellular signalling pathways for melatonin actions.
Copyright 2015, Mansoura University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Melatonin (N-acetyl-5-methoxytryptamine) was isolated from
the bovine pineal gland 55 years ago [1,2]. The rhythmic pro-
duction ofmelatonin by the pineal glandwas initially linked to
the regulation of seasonal reproduction in photoperiodic
species [3,4]. Subsequent studies have shown thatmelatonin's5.
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sity. Production and hosti
/licenses/by-nc-nd/4.0/).functions greatly exceed that of regulation of the waxing and
waning of seasonal reproductive competence [5,6].
Seasonal reproduction is an adaptive physiological process
utilized by animals that live under natural environmental
conditions to anticipate annual changes in day length, tem-
perature and food availability [7]. This allows them to make
the necessary physiological adjustments in advance of the
actual sexually quiescent interval or breeding period [8]. In(M.J. Anwar).
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of the ganglion cells of the retina and is transmitted via amulti
synaptic neural pathway to the pineal gland where the mes-
sage modulates the rhythm of melatonin secretion [9]. A
major function of the melatonin rhythm is to transmit infor-
mation about length of the daily dark period to the circadian
and circannual systems; thus it provides time-of-day and
time-of-year information, respectively, to the organism [10].
This information is essential for sleep, temperature regula-
tion, as well as for seasonal reproductive alterations [11e13].
Melatonin also is a powerful antioxidant and anti-
apoptotic agent, which due to its direct scavenging of toxic
oxygen derivatives and its ability to reduce the formation of
reactive oxygen species (ROS) and reactive nitrogen species
(RNS) prevents oxidative and nitrosative damage to all mac-
romolecules in all compartments of the cell [14e16].
Mammalian gametes and embryos are particularly vulnerable
to oxidative stress [17e19] due to plasma membrane compo-
sition, the presence of higher levels of lipids and exposure to
dramatic changes in the microenvironment, especially when
used in artificial breeding techniques [20,21]. Melatonin has
the ability to neutralize damaging ROS and RNS species in
these cells, reduce lipid peroxide concentrations and DNA
damage, and thereby improve the viability of germ and em-
bryonic cells [22e24]. The role of melatonin in the production
and preservation of mammalian gametes and embryos is
summarized in this brief review.2. Melatonin as an antioxidant
Despite of well known hormonal [25], sleep-inducing [26],
and chronobiological [27] effects of melatonin, antioxidant
properties have also been widely reported. Ianas and col-
leagues (1991) initially reported and claimed the antioxidant
and prooxidant actions of melatonin [28]. Therein they
generated free radicals using a combination of luminol and
H2O2 and used chemiluminescence as an index of free radical
production.
The free radical scavenging activity of melatonin was
studied in a battery of in vitro tests.Wherein they reported that
melatonin is devoid of prooxidant actions, at least in the series
of tests they performed [29]. Their findings are in line with the
previous observations, where they reported that melatonin is
an excellent scavenger of trichloromethylperoxyl (CCl3O2)
free radical [30,31]. Furthermore, they also found that
although melatonin reacts with hypochlorous acid (HOCI),
though the reaction is slow but it does not directly scavenge
the O2
 free radicals.
Recently several publications have reported the evidence
for cardioprotective effects of melatonin via its direct free
radical scavenger and its indirect antioxidant activity [32].
Melatonin efficiently interacts with various reactive oxygen
and reactive nitrogen species (receptor independent actions)
and it also upregulates antioxidant enzymes and down-
regulates pro-oxidant enzymes (receptor-dependent actions)
[31]. The lipophylic nature of melatonin allows its entry
into the cells and subcellular compartments and to cross
morphophysiologic barriers. These findings implicate the
protective effects of melatonin in cardiac diseases induced byoxidative stress. Its direct free radical scavenging activity [33]
and its regulation of gene transcription [34] for antioxidative
enzymes has been reported in the literature [35]. The
antioxidant properties of melatonin have been extensively
studied and summarized its use as a cell protector and as a
potential disease-preventing agent [36e39]. Further, mela-
tonin has been proven to be an efficient oxidant scavenger of a
variety of radical and non-radical reactants [40]. In addition to
this, it has been shown that this neurohormone is able to
increase the activity of glutathione peroxidase in rat brain
cortex as well as the gene expression for some antioxidant
enzymes [41].3. Melatonin as an oncostatic
Several preclinical and clinical studies have reported the
beneficial effects of melatonin against a wide range of tumour
[42,43]. Most of these studies focus on hormone-dependant
cancers related to disorder of endocrine system included
breast, prostate, uterus, cervical uterine, mammary tumours
[44], tumour growth, osteosarcoma [45]. Impaired secretion of
melatonin has been reported in patients suffering frombreast,
endometrial, or colorectal cancer [46]. Further increased inci-
dence of breast and colorectal cancer observed in nurses and
other night-shift workers suggests a possible correlation be-
tween the reduced melatonin secretion and their increased
light exposure at night [47,48].
Melatonin exhibits the oncostatic action by its two main
properties firstly by protective effect such as reversible cellular
injury [49] through neurohormone regulation and secondly by
antiproliferative effects. Moderation of cellular cGMP and cAMP
ratios regulates cellular metabolic processes and thus control
the production of antioxidants in the cell. Melatonin defi-
ciency results in uncontrolled cAMP synthesis, leading to
unregulated oxidative processes and subsequent free radical
damage [50]. Alterations of the intracellular redox state play a
key role in the effects of high concentrations of melatonin in
cancer cells, reducing conditions being associated with a
decrease in cell proliferation and oxidative conditions with
apoptosis [51]. Melatonin mediates suppression of cAMP
levels throughmelatonergic receptor and thus inhibits uptake
of mitogenic substances involves on growth of tumour [52]. It
has been demonstrated in various carcinoma cell lines that
melatonin increases the activity of glutathione-S transferase
enzyme (GST) implicating the role of GST gene on 11q 13
chromosome in cancer [53]. This is supported by the study
wheremelatoninwas reported to bound to DNA, chromatin or
heterochromatin [10].
Melatonin shows antigonadotropic and antioestrogenic
actions in different study module, in vitro and in vivo on
hormone-dependent tumours and cancer cell line [44] as well
as antagonised the action of prolactin on human breast cancer
cell (HBC) [54]. It selectively neutralised the effects of estro-
gens on the breast and the local biosynthesis of estrogens
from androgens [55]. It has reported thatmelatoninmodulates
the enzymes involved in the local synthesis of estrogens by
regulating the estrogen receptor expression and trans-
activation. Further, it has been reported that melatonin acti-
vates the immune system [56]. Recently it has been reported
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gastric adenocarcinoma tissues, in consistent with other
studies reported high expression in marginal tissues in breast
and colon cancer indicates a refractory mechanism and
defending role of melatonin in GI system [57].
Secondly the oncostatic property such as antiproliferatlve
effects on MCF-7 cell growth in culture [58], modulation of
cell cycle and induction of apoptosis, inhibition of telomerase
activity [56], and antiangiogenesis. Melatonin exerts an anti-
angiogenic activity in HepG2 cells by interfering with the
transcriptional activation of vascular endothelial growth fac-
tors (VEGF), via hypoxia-inducible factor 1-alpha (Hif1a), and
signal transducer and activator of transcription 3 (STAT3) [59].
Melatonin is a broad-scale epigenetic modulator of gene
expression [60] and stimulation of cell differentiation [56]. It
shows apoptosis of Ehrlich ascites carcinoma (EAC) cells and
phase delay of the cell cycle [53]. Gonzalez et al. demonstrated
that melatonin shows oncostatic effect in MCF-7 human
breast cancer cells by melatonin receptor 1 (MTR1) thus con-
firms MTR1 as a main mediator in the melatonin signalling
pathway in breast cancer [61]. Further, melatonin inhibits
aromatase activity and expression by regulating the gene
expression of specific aromatase promoter regions [62].
Melatonin plays an important role in different stages of
cancer (tumour growth and metastasis) through different
pathways and it may have therapeutic significance [63].
Melatonin was used as an adjunct to the routine chemo-
therapy of osteosarcoma, it helps to improve the prognosis of
this diseases [45]. Melatonin decrease bone resorption and
have a bone protecting effect [64]. The future holds much
promise for melatonin as a therapeutic treatment. High
expression levels ofMT1-mRNA together with lowOPG-mRNA
were found in both osteosarcoma cell lines, while in normal
human osteoblasts and bone marrow stromal cells, high OPG-
mRNA levels were associated with low MT1-mRNA levels.
These data on the abundant expression of MT1-mRNA in
human bone tumors and osteosarcoma cells lines suggest an
important role for MT1 in bone pathology [65]. Recently, one
study investigated the effect of melatonin on proliferation of
human osteosarcoma cell line MG-63 wherein they reported
that melatonin significantly inhibit human osteosarcoma cell
proliferation in a dose-dependent and time-dependent
manner and this inhibition involves the downregulation of
cyclin D1, CDK4, cyclin B1 and CDK1 [66].4. Melatonin as a hypnotic
The first clinical evidence for the involvement of melatonin in
sleepwas observed by Lerner [1]. Melatoninwas intravenously
administered at a dose of 200 mg to two volunteers who
became sleepy. Subsequently Lerner and his collaborators
treated 5 patients with hyper-pigmentation using prolonged
ingestion of 1 g melatonin daily where they observed that all
patients became drowsy [67]. More than 15 studies showed
that melatonin promoting sleep in healthy volunteers [68].
Thus melatonin as hypnotic analogues is made over counter
for healthy individuals who want to improve their sleep.
Melatonin, being described as chronobiotic molecule [69]
has also been used successfully for treatment of sleepproblems related to perturbations of the circadian time
keeping system like those caused by jet lag and shift-work
disorder [68]. An irregular work schedules have been associ-
ated with a loss of daily rhythms and increasingly fragmented
sleep [70,71]. Previous studies showed the beneficial effect of
melatonin and its hypnotic analogues on sleep disorder in
shift worker to rebalance the sleep-wake cycle and promotion
of sleep [72]. In addition to this, several studies reported
that melatonin is used to counteract jet lag, associated with
travel results due to changes in time zone in both adult and
children [73,74].
Metabolic syndrome (MS) patients exhibit sleep/wake dis-
turbances and other circadian abnormalities, and these may
be associated with more rapid weight increase and develop-
ment of diabetes and atherosclerotic disease. Melatonin and
its hypnotic analogues (ramelteon, agomelatine, tasimelteon)
showed beneficial effects on sleep disturbances associated
with various diseases include neurological, psychiatric, car-
diovascular and metabolic diseases [75]. Being an effective
chronobiotic agent, melatonin is able to change the phase and
amplitude of circadian rhythms. It has also significant cyto-
protective properties preventing a number of MS sequelae in
animal models of diabetes and obesity. Further, melatonin
showed therapeutic beneficial in treatment of sleep disorder
associated with obesity [76]. Sleep disturbances are a frequent
problem in cancer patients; melatonin can attenuate
insomnia and improve quality of life [77]. In diabetes, sleep
disturbance is common and melatonin and its analogues
exerted beneficial effects. Other studies evaluated the efficacy
of melatonin in promoting better sleep in persons with pri-
mary insomnia. Meta-analysis study reported that melatonin
decreases sleep onset latency, increases total sleep time and
improves overall sleep quality [78]. Moreover melatonin and
its hypnotic analogues replacement therapy have been shown
to be beneficial in treating elderly insomniacs [68,79]. Further,
the British Association of Psychopharmacology recommended
melatonin as the first choice treatment of insomnia in elderly
insomniac patients.
Hypnotic analogues of melatonin include ramelteon, tasi-
melteon and a chlorinated derivative ofmelatonin TIK-301 are
approved by the FDA for treatment of insomnia during
2005e2010. All the hypnotic analogues act on MT1/MT2
melatonin receptor [80]. The FDA granted tasimelteon and
TIK-301 orphan drugs designation status for blind individuals
without light perception with non-24-hour sleep-wake disor-
der between 2004 and 2010. The FDA granted orphan drugs to
use as a treatment for circadian rhythm sleep disorder in blind
individuals without light perception [77]. Melatonin hypnotic
analogues (MHAs) have limited potential for abuse, cognitive
and functional impairment due to the fact that they are devoid
of affinity for benzodiazepine, dopamine, and opiate, ion
channels and receptor transporters. MHAs showed safety
more than triazolam and benzodiazepine derivatives. Because
MHAs such as ramelteon caused no significant effect on these
problematic adverse events at up to 20 times the recom-
mended dose (8 mg daily at bedtime) [81]. There were no
apparent next-day cognitive or motor effects or evidence of
rebound insomnia or withdrawal effects following treatment
discontinuation. MHTA were considered for patients with
sleep-onset insomnia, particularly those who are treatment
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adults susceptible to the effects of benzodiazepine and non-
benzodiazepine hypnotics, and who require minimal inter-
ference with the arousal response [82]. Melatonin agonists are
potentially efficacious and safe drugs in the treatment of co-
morbid insomnia with add-on positive effects in a variety of
neurological, psychiatric, cardiovascular and metabolic dis-
orders [75].
In contrary to this, a meta-analysis, undertaken by Brze-
zinski et al. [83] using 17 different studies involving 284 sub-
jects, most of whom were older, concluded that melatonin is
effective in increasing sleep efficiency and reducing sleep
onset time. Based on this meta-analysis, the use of melatonin
in the treatment of insomnia, particularly in aged individuals
with nocturnal melatonin deficiency, was proposed.
Melatonin affects sleep and the sleep-wakefulness cycle by
acting on receptors in the hypothalamic suprachiasmatic
nuclei (SCN) [84]. It shows increased non-rapid eyemovement
(NREM) sleep in rat [85]. In diurnal species, suppression of
electrical activity in the SCN is suggested as the possible
mechanism by which melatonin regulates sleep [86]. Further,
these effects are thought to bemediated throughMT1 because
knockout mice for MT1 receptor gene are devoid of sleep [87].
The suppression of neuronal activity by melatonin is one of
the possible mechanisms by which this hormone contributes
to the regulation of sleep [68]. The high density of melatonin
receptors in the hypothalamic suprachiasmatic nuclei (SCN)
[84] suggested that melatonin affects sleep and the sleep-
wakefulness cycle by acting on these receptors. Local injec-
tion of pharmacological amounts ofmelatonin (1e50 mg) in the
medial preoptic area of the rat hypothalamus during daytime
increased non-rapid eye movement (NREM) sleeps [85].
Melatonin receptors are members of the G protein-coupled
receptor (GPCR) family. M1 is a Gi/o protein-coupled receptor
linked, in part, to pertussis-toxin sensitive G proteins that
mediate inhibition of cAMP in both recombinant expression
systems and native tissues. M2 is a Gi/o protein-coupled re-
ceptor capable of inhibiting cAMP and cGMP production in
recombinant systems and stimulating PKC activity in a native
tissue, the SCN [88]. Three genes for melatonin receptors have
been cloned. TheMT1 (orMel1a orMTNR1A) andMT2 (orMel1b
or MTNR1B) receptor subtypes are present in humans and
other mammals. Gene polymorphisms reveal that numerous
mutations are associated with diseases and disorders. The
phylogenetic analysis of receptor genes indicates thatGPR50 is
an out-group to all other melatonin receptor sequences [66].
Genetic polymorphisms have been reported for melatonin
receptors in human. Seven mutations were found in the MT1
receptor, with two that resulted in amino acid changes: R54W
in the first cytoplasmic loop and A157V in the fourth trans-
membrane domain. Twomutations were also reported for the
hMT2: G24E in the N-terminal domain and L66F in the first
cytoplasmic loop. However, neither shows altered MT1 MT2
receptor binding characteristics [89]. The effect of these mu-
tations in melatonin receptor function has not been reported.
Melatonin has been shown to induce sleep by altering the
functions of the GABAA-benzodiazepine receptor complex by
increasing both amplitude and frequency of GABAergic and
enhances GABAergic inhibitory transmission in cultured rat
hippocampal neurons [90].5. Melatonin as antidepressant
The master biological clock resides in the suprachiasmatic
nuclei of the hypothalamus, a small bilaterally paired struc-
ture just above the optic chiasm and plays key role in
orchestrating the circadian rhythms of multiple biological
processes. Increasing evidence points to a role of the biolog-
ical clock in the development of depression as it drives 24h-
rhythms in physiology and behaviour, and aligns endogenous
rhythms to the external solar day in a close temporal rela-
tionship. Disturbance of sleep and circadian rhythms is a
prominent feature of depression, and therefore, regarded as
central for understanding the pathophysiology and treatment
of depression. Though contradictory, disrupted melatonin
secretion is regarded as a link between circadian rhythm and
major depression. In 2011, Quera et al. reported that antide-
pressants with intrinsic chronobiotic properties could offer a
novel approach to treatment of depression [91]. Melatonin and
melatonin agonists have been reported to possess chrono-
biotic effects, which mean that they are able to readjust the
circadian system. It was suggested that seasonal affective
disorders and mood disturbances caused by circadian mal-
function could be treated by manipulating the circadian sys-
tem using chronobiotic drugs, chronotherapy or bright light
therapy. In major depressive disorder, melatonin per se
showed no antidepressant action but novel melatoninergic
compounds have demonstrated antidepressant properties.
Abnormal melatonin rhythms have been noted in several
diseases including depression in shift workers [92].
In 2013, in a preclinical study on mice, Haridas et al. eval-
uated possible beneficial action of chronic night-time mela-
tonin treatment against chronic mild stress-induced
behavioural impairments. It was reported that chronic mela-
tonin administration during night-time significantly amelio-
rated stress-induced behavioural disturbances, especially the
cognitive dysfunction and depressive phenotypes, and sug-
gested that melatonin mitigates chronic mild stress-induced
behavioural changes, including the cognitive dysfunctions
and reaffirm its potential role as an antidepressant [93].
The circadian rhythm hypothesis of bipolar disorder sug-
gested a role for melatonin in regulating mood and hence,
melatonergic antidepressant, agomelatine as well as type I
(acute) or II (cases of bipolar depression) have been investi-
gated as novel therapies. In a study involving 28 bipolar
disorder type eII (BD-II) patients who received open label
agomelatine (25 mg/bedtime) for 6 consecutive weeks as an
adjunct to treatment with lithium or valproate, followed by an
optional treatment extension of 30 weeks, the intent to treat
analysis results showed that 18 of the 28 subjects (64%)
responded to medication after 6 weeks (primary study
endpoint), while 24 of the 28 subjects (86%) showed response
by 36 weeks. The study concluded that agomelatine, 25 mg/
day, was an effective and well-tolerated adjunct to valproate/
lithium for acute depression in BD-II. However, authors sug-
gested the need to confirm the findings in double blind,
controlled clinical trials [94].
Recently in a systematic review and meta-analysis re-
ported that there was no clear evidence of a therapeutic- or
prophylactic effect of melatonin against depression or
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[95]. In MELODY trial, 6 mg oral melatonin was investigated on
depressive symptoms, anxiety, sleep, cognitive function and
fatigue in patients with breast cancer in a three month time
period post-surgery. Melatonin had an effect on reducing the
risk of developing depressive symptoms and also increased
sleep efficiency perioperatively and total sleep time post-
operatively [96]. A randomized, double-blind, placebo-
controlled trial melatonin significantly reduced the risk of
depressive symptoms in women with breast cancer during a
three-month period post-surgery [97].
An ideal antidepressant should not only reduce sleep onset
difficulties, but also provide daytime alertness and freshness.
Melatonin is free of adverse effects such as a ‘hangover’ and
has no abuse potential; in addition, it has been shown to
improve sleep patterns in patients with insomnia associated
with depression [98]. Melatonin exerts its antidepressant ef-
fect through antagonism of the 5HT receptor. It acts through 2
G-protein coupled receptors, MT1 (MEL1a) and MT2 (MEL1b).
The most advanced is the novel melatonin agonist agomela-
tine, which combines joint MT1 and MT2 agonismwith 5-HT2C
receptor antagonism. Adding a chronobiotic effect to the in-
hibition of 5-HT2C receptors may explain the rapid impact of
agomelatine on depression, since studies showed that ago-
melatine had an early impact on sleep quality and alertness at
awakening. Agomelatine was approved for the treatment of
major depressive disorder in adults by the European Medi-
cines Agency in February 2009. It is an analogue of melatonin
and features a unique pharmacodynamic profile with ago-
nism on both types of melatonergic receptors (MT1/MT2) and
antagonism at serotonergic 5-HT2C receptors. It has been
referred to as an effective antidepressant agent in the acute
phase of major depressive disorder due to its statistically
significant advantage over placebo based on the results of two
recent comprehensive meta-analyses of published and un-
published clinical trials [99]. It lacks affinity for histaminergic,
adrenergic or dopaminergic receptors. However, despite its
efficacy agomelatine was reported to have the potential to
exhibit severe hepatotoxic reactions as a new safety concern
and is currently poorly understood [99]. Hence, for now it was
suggested that it cannot be deemed as antidepressant agent of
first choice.
Recently, it has been demonstrated that MT2 receptors
are involved in the pathophysiology and pharmacology of
sleep disorders, anxiety, depression, Alzheimer disease and
pain. Further selective MT2 receptor agonists have shown
hypnotic and anxiolytic effect. However, the development of
selective MT2 receptor ligands and their preclinical evaluation
revealed the role ofMT2 receptor in regulating brain functions.
Further, the MT2 receptors offer great potential for drug dis-
covery [100].6. Melatonin as antiepileptic
Treatment for epileptic complications continue to pose chal-
lenge because of the poor adherence and drug interactions
associated with multi drug prescriptions and also for the fear
of worsening seizures by the individual medications for
complications.Melatonin, an endogenous hormone secreted by pineal
gland has a prominent role in epilepsy. The ability of mela-
tonin to cross the bloodebrain barrier gives hope that it could
be useful in the treatment of seizures. Melatonin was reported
to modulate the electrical activity of neurons by reducing
glutamatergic and enhancing GABA-ergic neurotransmission.
The hormone and its metabolites act as free radical scaven-
gers and antioxidants. The results from a recent study have
shown that melatonin inhibits neurotransmitter release
through the blocking of voltage-sensitive Ca2þ channels sug-
gesting a possible mechanism for the antiepileptic effect of
melatonin [101].
High doses of melatonin (20 mg/kg) given to mice under-
going electroconvulsive stimulation resulted in a strong long-
term memory deficit, although electroconvulsive stimulation
can also be linked to memory deficit. However, melatonin is
well tolerated in doses up to 800 mg/kg in mice [102]. Later, a
vast majority of experimental and clinical data have indicated
anticonvulsant properties of the hormone. Melatonin inhibi-
ted audiogenic and electrical seizures, as well as reduced
convulsions induced by pentylenetetrazole, pilocarpine, L-
cysteine and kainate [103]. In 2011, a study by Lima et al.
investigated the effects of treatment with melatonin and N-
acetylserotonin on the pilocarpine-induced epilepsy model.
They concluded that melatonin exerted an important neuro-
protective effect by attenuating status epilepticus (SE)-
induced post lesion and promoting a decrease in the number
of seizures in epileptic rats. The authors suggested, for the
first time, that melatonin could be used co-therapeutically in
treatment of patients exhibiting SE to minimize associated
injuries in these situations [104]. A recent study confirmed
that long-termmelatonin treatment after SE has a potential to
attenuate seizure activity and neuronal loss, it was unable to
restore epilepsy-associated behavioural abnormalities in
spontaneously hypertensive rats [105]. Melatonin exhibited an
additive effect with another anticonvulsant drug in
decreasing pentylenetetrazole-induced seizure threshold in
mice, probably through melatonin MT1/2 receptors [106]. In
2013, Tchekalarova et al. examined the effect of melatonin
treatment (10 mg/kg/day, diluted in drinking water, 8 weeks)
during epileptogenesis on the consequences of a kainate-
induced status epilepticus in rats. They reported that mela-
tonin increased the latency in the appearance of spontaneous
recurrent seizures and decreased their frequency only during
the treatment period. The behavioural alterations associated
with hyperactivity, depression-like behavior during the light
phase, and deficits in hippocampus-dependent working
memory were positively affected by melatonin treatment in
rats with epilepsy. Melatonin reduced the neuronal damage in
the CA1 area of the hippocampus and piriform cortex and
recovered the decrease of hippocampal 5-HT level in rats with
epilepsy. Tchekalarova et al. concluded that long-term mela-
tonin treatment after SE did not suppress the development of
epileptogenesis but have a potential in reducing some of the
deleterious alterations that develop during the chronic
epileptic state in a diurnal phase-dependent mode [107]. In
2013, a preclinical study reported that melatonin significantly
potentiated the anticonvulsant efficacy of phenobarbital,
but did not exert anticonvulsant effects on its own. The data
from this study provided additional evidence for the further
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pediatric epilepsy [108]. Melatonin reduces seizure latency
and frequency, and improves electroencephalography (EEG)
tracing [109]. In a study of 14 patients of the age of 2e19 years,
complete disappearance of seizures was observed with
melatonin therapy. Such therapy is known to reduce seizure
latency in young children as well as adults with different
kinds of epilepsy [110]. Subsequently, many studies were
conducted to examine the role of melatonin in epilepsy and
have revealed that, as an adjunct, melatonin helps to improve
seizure management, although the effects of melatonin alone
have yet to be explored [111]. In a study on 23 children with
intractable epilepsy and 14 children with controlled seizures,
use of melatonin in children with intractable seizures was
associated with improvement of both many sleep-related
phenomena and the severity of seizures [112]. In 2011,
another clinical study, reported that melatonin was a good
regulator of the sleep-wake cycle for paediatric patients
suffering from severe epilepsy and suggested it to be a better
control of convulsive episodes [113]. In 2012, Goldberg-Stern,
in a pilot study, examined the effect of melatonin on sei-
zures, sleep quality, and behavior in 10 patients aged 9e32
years with intractable epilepsy. The study concluded that
melatonin could be effective and safe for decreasing daytime
seizure frequency in patients with intractable epilepsy [114].
Another important consideration is that melatonin
administration reduces the seizure threshold andmight act as
a proconvulsant [110] and some study have shown no anti-
convulsant effect with melatonin. In 2009, a study reported
that serum melatonin levels decreased in children with epi-
lepsy or complex febrile seizure (FS), and supplement of
exogenous melatonin might be a promising treatment for
epilepsy and febrile seizures in children [115]. However,
recently, Mahyar et al. determined the relationship between
serummelatonin levels and FS and epilepsy in children. They
revealed that there was no association between serum mela-
tonin level and simple or complex FS and epilepsy. Also, they
reported that melatonin played no significant role in these
convulsive disorders [116]. Because of the increasing evidence
favouring anticonvulsant activities of melatonin, large rand-
omised double-blind trials are warranted to establish mela-
tonin as a novel anticonvulsant drug.7. Melatonin as immunomodulator and anti-
inflammatory
Some clinical studies reported that melatonin could be
capable of protecting gastrointestinal mucosa against damage
through stimulating the immune system and fostering
microcirculation and epithelial regeneration [117]. Melatonin
has been shown to be involved in the regulation of both
cellular and humoral immunity. Melatonin not only stimu-
lates the production of natural killer cells, monocytes and
leukocytes, but also alters the balance of T helper (Th)-1 and
Th-2 cells mainly towards Th-1 responses and increases
the production of relevant cytokines such as interleukin (IL)-2,
IL-6, IL-12 and interferon-gamma. The regulatory function
of melatonin on immune mechanisms is seasonally depen-
dent [118].Furthermore, it has been reported that melatonin certainly
plays an important role in regulation of epithelial functions as
well as significant anti-inflammatory and anti-apoptotic ef-
fects. The probable mechanism of melatonin could be attrib-
uted due to its ability to reduce bacterial translocation and its
anti-apoptotic effect and therefore it can reduce the extent of
mucosal damage. This finding suggests that melatonin exert a
beneficial role in human inflammatory bowel disease (IBD)
through reduction of the tumor necrosis factor-a (TNF-a)
levels [119]. In addition to this, melatonin also can decrease
free radical levels by stimulating the activities of enzymes
involved in antioxidative defence [120].
However, in an experimental model of colitis it was shown
that short-term administration of melatonin is protective
while in the long term it negatively influences evolution of
inflammatory colitis. Therefore, the immuno-stimulatory
effect of melatonin in some situations when given chroni-
cally, such as during inflammatory bowel disease could have
negative consequences [121].
Inflammation is an essential response to tissue injuries
induced by physical, chemical or biological insults. The ner-
vous and endocrine systems can interact with the immune
system in order to modulate its function. Melatonin is able
to modulate immune functions through its neuro-endocrine
action; where its primary role is a regulator of circadian
rhythms in a hormone-like fashion by affecting target
cells [122].
Furthermore, melatonin can modulating other functions
depending on the photoperiod including regulation of photo-
periodic oscillations of the immune/inflammatory response;
where leukocytes possess melatonin specific receptors
including bothMT1/MT2 and nuclear RZR/ROR alpha receptor.
This provides the molecular basis for the sensitivity of leu-
kocytes tomelatonin, and hence it is considered as pleiotropic
molecule that can regulate inflammation by different prop-
erties [123].
Melatonin exerts a concentration-dependent effect on the
immune system. Indeed, increasing concentrations of mela-
tonin induce T cell proliferation in a dose-dependent way.
Whereas in some experimental studies reported that exoge-
nous melatonin administration was found to increase the
proliferative response of rat lymphocytes, increases the
number of nature killer cells [124].8. Melatonin as chronobiotic molecule
As per the International Classification of Sleep disorders,
delayed sleep phase disorder (DSPD) is characterised by diffi-
culty in falling asleep at their desired bedtime and an inability
to wake spontaneously at the planned time in the morning.
Delayed sleep phase disorder was first defined it as disorder
and described as long sleep onset latencies and late sleep
onset times caused by a delay of the major sleep period.
In 2005, Arendt and Skene [125] reviewed the effects of
melatonin especially as a chronobiotic molecule wherein they
agreed upon that melatonin is secreted at night in humans
and it is thereby associated with sleep and other night time
events. The period of melatonin secretion has been described
as 'biological night'. Its main function in mammals is to
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organisation of day-length dependent changes, such as
reproductive competence. Exogenous melatonin has acute
sleepiness-inducing and temperature-lowering effects during
'biological daytime', and when suitably timed it will shift the
phase of the human circadian clock to earlier or later times.
The shifts induced are sufficient to synchronise to 24 h most
blind subjects suffering from non-24 h sleep-wake disorder,
with consequent benefits for sleep. Recently one study re-
ported the successful use of melatonin as chronobiotic
molecule in other sleep disorders associated with abnormal
timing of the circadian system: jetlag, shiftwork, delayed sleep
phase syndrome, some sleep problems of the elderly. Regu-
lation of pineal melatonin biosynthesis is largely explained by
control mechanisms acting on arylalkylamine N-acetyl-
transferase, at the levels of gene expression and/or enzyme
stability influenced by phosphorylation and interaction with
14-3-3 proteins [126]. Further, it has been suggested that nu-
clear orphan receptors (NOR) can be regulated by the mela-
tonin circadian rhythm in the pars tuberalis (PT) and could be
the link between the physiological action ofmelatonin and the
core of the molecular circadian clock in this tissue [127].
There is ample of evidence that DSPD arises from a delayed
endogenous circadian rhythm [128]. DSPD and sleep onset
insomniacs have altered sleep parameters, melatonin and
core body temperature as compared to control groups [129]. If
the core body temperature and melatonin circadian rhythms
were phase delayed, then the “wake maintenance zone”
would be delayed also. Although circadian rhythm phase
delay is seen as themajor contributor to DSPD, there are some
important behavioural and cognitive factors that should be
addressed to improve treatment effectiveness.
The ability of exogenous melatonin to phase advance
circadian rhythms suggests that it will be effective in the
treatment of instrinsic DSPS. Further, exogenous melatonin
administration also is capable of shifting the circadian rhythm
to a more desired time [130]. In the evening phase, melatonin
advances circadian rhythm when combined with optimal
time of administration and greater doses: (3e5mg) 4e8 h prior
to the onset of endogenous melatonin and smaller doses
(0.3e0.5mg) 3 h before the beginning ofmelatonin production.
In the first placebo controlled crossover study, melatonin
(5 mg fast release) was given at 22:00 h (5 h before sleep onset)
to eight men with DSPS [131]. Melatonin has advanced the
sleep onset and wake time (P < 0.01) as compared to placebo.
Moreover, the beneficial effects of melatonin have been
demonstrated in 25 DSPS patients whenmelatonin (5 mg) was
given earlier (5 h before melatonin onset z7 h before sleep
onset) [132]. However the lower doses (0.3e1.0 mg) of mela-
tonin have also been assessed at 1, 3 and 5 h before the sleep
onset. In line with this previous study showed that the addi-
tion of evening melatonin administration to morning bright
light therapy produced a significantly greater phase advance
than the morning bright light alone, suggesting that the two
therapies are additive [133]. The magnitude of phase shift is
affected by the timing, duration of light stimulus, brightness
and thewavelength of light. The human phase response curve
to light suggests that a phase advance of the circadian rhythm
is achieved when the light stimulus is presented immediately
after the normal circadian time (CT) [134].Although exogenous melatonin appears to be safe with
short-term use (less than 3months), there is little information
available on its long-term administration. However it is judi-
cious to use much lower doses of melatonin because typical
doses (3e5 mg) in many studies can elevate melatonin con-
centrations well above normal physiological plasma levels.
Fortunately, the chronobiotic effects of low doses (0.3e0.5 mg)
appear to be sufficient without requiring excessive supra-
physiological levels. The adverse side effects associated with
melatonin administration include headache, dizziness,
nausea, and drowsiness [135]. The effect of exogenous mela-
tonin on sleep was the object of a recentmeta-analysis report,
which states: “thismeta analysis supports the hypothesis that
melatonin decreases sleep onset latensy, increases sleep ef-
ficiency and total sleep duration [136]. In spite of the hetero-
geneity of the data the present meta analysis does land
statistical support to the notion that melatonin preparations
can improve sleep quality with regard to sleep onset latency,
sleep efficiency and sleep duration.”9. Melatonin in cardiovascular disease
Many of deleterious agents and pathomechanisms such as
ischemia/reperfusion, arterial and coronary atherosclerosis,
hypertension, and cardiotoxic drugs can producing or/and
processing free radicals harmful impact on cardiac physi-
ology; thus may cause of disability and mortality [137].
Melatonin attenuates molecular and cellular damages
resulting from cardiac ischemia/reperfusion in which
destructive free radicals are involved. Anti-inflammatory and
antioxidant properties of melatonin are also involved in the
protection against a chronic vascular disease, atherosclerosis.
The administration of melatonin, as a result of its antioxidant
features, has been reported to reduce hypertension and car-
diotoxicity induced by clinically used drugs and so melato-
nin's antioxidant effects are in fact due to its metabolites
which are generated when melatonin interacts with free
radicals [32].
Previous studies suggest that melatonin acts at the mito-
chondrial level which is responsible for its cell protective ef-
fect [138]. In line with this, Petrosillo et al. reported that
melatonin protects against mitochondrial dysfunction asso-
ciated with cardiac ischemiaereperfusion, by preventing al-
terations to several parameters involved in mitochondrial
bioenergetics [139]. Furthermore, the same authors demon-
strated that melatonin treatment significantly improves the
functional recovery of Langendorff hearts on reperfusion, re-
duces the infarct size and decreases necrotic damage. All
these effects appear to be due, at least in part, to the inhibition
of MPTP opening via prevention of cardiolipin peroxidation.10. Melatonin in bone disease
Melatonin plays a regulatory role in many physiological pro-
cesses including bonemetabolism [140]. Melatoninmay affect
bone metabolism through bone anabolic as well as anti-
resorptive effects. Bones are structures under a continuous
process of remodelating by the coupled activity of cells with
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formation of new bone (osteoblasts). Nocturnal plasma
melatonin levels significantly decline after the age of 50 in
both genders [141]. Since the time course of the reduction of
melatonin production and the progression of bone deteriora-
tion run in parallel shows possible role of melatonin in bone
metabolism.
It can prevent the premature destruction of bone and
promote its recovery through mechanisms of melatonin-
related receptors and receptors of independent action [142].
One study reported the role of melatonin and RANKL/RANK/
OPG system (receptor activator of nuclear factor-kappa B
ligand/receptor activator of nuclear factor-kappa B/osteopro-
tegerin) on the regulation of bone turnover [143]. Melatonin
regulates the bone metabolism both by its direct influence on
bone by acting on osteoclast as well as on osteoblast and
indirectly by down-regulating RANK-mediated osteoclast
formation and activation [144]. This mechanism brought a
discussion about the clinical use for melatonin in bone-
grafting procedures, in reversing bone loss due to osteopenia
and osteoporosis, and in managing periodontal disease.
Recently, an in vitro study demonstrates that melatonin pro-
motes differentiation and mineralization of cultured osteo-
blast cells (MC3T3-E1 cells) under hypoxic conditions [145].
Thus this study concludes that melatonin promotes osteo-
blastic differentiation of MC3T3-E1 cells under hypoxic con-
ditions via the p38 Mapk and Prkd1 signaling pathways.
A recently published study investigated the protective ef-
fects of melatonin as a direct therapeutic tool against
chlorhexidine-induced bone cell damage [146]. Wherein they
reported that melatonin protects osteoblasts, thereby impli-
cating melatonin as a promising drug in periodontitis and
peri-implantitis treatment. Although the study focused on the
morphological and pathological changes without obvious ef-
forts to prove it by suggesting a molecular mechanisms, sup-
porting cell morphogenesis and growth, reducing ROS and
superoxide generation, shifting the percentage of CHX-
damaged cells from necrotic/late to early apoptotic events,
and modulating metabolic activity in osteoblasts. In agree-
ment with this another in vitro study investigated the effect of
5-methoxytryptophol on bone cell function and observed that
melatonin needs higher dose to produce better osteoblastic
differentiation effects but this high dose could be toxic [147].
More promising result was obtained when focused on
bone sialoprotein (BSP), a mineralized connective tissue-
specific protein expressed in the early stage of cementum
and bone mineralisation where melatonin induce BSP tran-
scription via the CRE1 and CRE2 elements in the human BSP
gene promoter [148].
As a treatment of age related bone loss, there is a primary
evidence of that dietary melatonin supplementation is able to
exert beneficial effects against age-related bone loss in old
rats, improving the microstructure and biomechanical
properties of aged bones [149]. A new prospect of using
melatonin as a bone therapy had been investigated, where the
investigators tested a melatonin graft on a rabbit's tibia
instead of procaine bone graft to accelerate the bone forma-
tion. The study also revealed that melatonin has proven to
regenerate the width and length of cortical bone in tibiae
rabbits more quickly than collagenized porcine bone.Melatonin acts as a bone stimulator compared with porcine
bone and control sites [150].
Moreover, the potential beneficial effects of melatonin on
rabbit tibial bone repair have been investigated wherein they
reported that this effect could be associated with angiogen-
esis and increase in bone density [151]. Similar report was
observed by another investigators where they observe that
the administration of melatonin may be beneficial in sup-
pressing the effects of free oxygen radicals and regulating
antioxidant enzyme activity in the fracture healing process
[152]. However, the fracture healing ability of melatonin was
investigated by Histing et al., where they observed that
melatonin protects the bone from fracture evidenced by
radiological, biomechanical, histomorphometrical, and pro-
tein biochemical analyses at 2 and 5 wk after fracture. The
study concludes that as the bone resorption is an essential
requisite for adequate remodeling during fracture healing,
melatonin impairs fracture healing by suppressing bone
resorption through down-regulation of RANKL-mediated
osteoclast activation [153]. Interestingly, as a bone protec-
tive therapy against osteoporosis, melatonin was investi-
gated on the perimenopausal women where it was observed
that melatonin supplementation was well tolerated;
improved physical symptoms associated with perimeno-
pause, and may restore imbalances in bone remodeling to
prevent bone loss. But further investigation is warranted to
justify this effect [154].11. Melatonin as neuromodulatory molecule
It has been demonstrated that melatonin may modulate the
function of various types of neurons in the central nervous
system (CNS) by modifying the activity of ligand- and voltage-
gated ion channels [155,156]. These actions of melatonin on
central neurons are mediated by distinct intracellular path-
ways via activation of different subtypes of melatonin re-
ceptors. Exogenous administration ofmelatonin elevates both
brain Bcl-2 and BDNF levels. Melatonin acts through the mir-
ochondrial pathway and blocks the spill of cytochrome c to
the cytosol and thus prevents activation of caspases,
increasing cellular content of Bcl-2 in old rats and thus re-
duces apoptosis. Further melatonin regulates the complex
Bax/Bcl-2 and antagonises apoptosis through the activation of
Mitogen activated protein kinase/Extracellular signal-
regulated kinases (MAPK/ERK pathway) and inhibition of
stress kinases JNK and p38 MAPK in neuronal cells [157].
Melatonin and its activated receptors have been linked to the
regulation of neurotrophic factors, including BDNF. Both G-
proteins-mediated signalling and other pathways such as
extracellular signal-regulated kinase (ERK) may contribute to
melatonin action on BDNF [158].
Further, melatonin exerts beneficial effects on cholinergic
neurotransmission in the brain by increasing the activities of
choline acetyl transferase (ChAT) enzyme in the frontal cortex
and hippocampus [158]. In addition to this, melatonin directly
detoxifies free radicals and thus can enhance brain Ach ac-
tivity as a result of the presence of an electron rich aromatic
indole ring as an electron-donor.
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In all vertebrates, the indolamine melatonin is secreted from
the pineal gland during the hours of darkness and acts as a
hormonal message of the photoperiod. Melatonin is the final
product of tryptophan metabolic pathway. The activity of
tryptophan hydroxylase (TPH) determines the quantity of
serotonin in the gland. Light-dark cycle and clock-driven
rhythms affects the expression of TPH mRNA, peak levels
of both occur at night [159] coincident with maximal mela-
tonin generation. The low level of precursor is not the
rate limiting in melatonin biosynthesis since the amount of
serotonin in the pineal gland is reportedly exceptionally
high [160].
The biosynthesis of melatonin from serotonin is generally
considered to be coupled with arylalkylamine N-acetyl-
transferase (AANAT) activity [161]. Moreover the rhythm of
pineal AANAT runs parallel with that of pineal and blood
melatonin level, which are usually high at night [162,163]. The
circadian rhythm in the anterior hypothalamus regulates the
24 h oscillations in AANAT activity and melatonin production
[9]. The elevated production of melatonin at night is regulated
primarily through b1-adrenergic receptors by post-ganglionic
sympathetic nerve ending [164]. However, it has been also
reported that pineal gland is also innervated by para-
sympathetic nervous system but it has negligible importance
in melatonin production [165].
Norepinephrine (NE) release from sympathetic nerve end-
ings is the primary stimulus for nocturnal melatonin syn-
thesis in pineal gland. Moreover it is expected that some
stressful stimuli that augment release of NE from other sites,
elevating circulating catecholamine, would reach at pine-
alocyte stimulates daytime melatonin synthesis. However
this does not occur because the sympathetic nerve endings in
the pineal gland acts as an effective sink and thereby
sequester excess circulating NE [166].
In mammalian species, melatonin disappears from the
circulation as a result of 6-hydroxylation in the liver, followed
by excretion in a sulfatoxy-conjugated form. The half-life of
melatonin in plasma is about 10 min, due to a rapid hydrox-
ylation to 6-hydroxymelatonin in the liver. In the apparent
absence of storage or regulated secretion of the hormone,
melatonin levels in blood directlymirror the rate of melatonin
production.13. Melatonin: receptors and signal
transduction
The alteration of cellular physiology by melatonin is medi-
ated via membrane receptors. In addition to this some re-
ceptor independent action of melatonin is mediated by its
ability to scavenge free radicals and related reactants. MT1
and MT2 are the two major membrane bound G protein
coupled receptors for melatonin. They differ in affinity for
their natural ligand, melatonin. To date, the MT3 receptor
has been found in the liver, kidney, brain, oocyte and ovary
[167e169] and is seemingly identical to the cystosolic
enzyme, quinone reductase 2 (QR2) [170]. Melatonin exerts itsaction by generating a variety of different second messenger
after its binding to membrane receptors depending on the
specific cell and on the species. A major means by which the
MT1 and MT2 receptors regulate intracellular processes is via
an inhibition of adenylate cyclase, a reduction in cAMP and
modulation of protein kinase A (PKA) activity; this action
involves a pertussis toxin sensitive Gi protein [171]. Further it
has been reported that activated MT1 receptor inhibit cAMP
response-element-binding protein (CREB) phosphorylation
and formation of immediate early gene products such as c-
fos and jun B [172].
MT1 and MT2 receptors, upon stimulation activates phos-
pholipase C-b and thereby increases the production and
release of inositol-(1,4,5)-triphosphate (IP3) and 1,2-
diacylglycerol [173]. Stimulation of MT1 is also accompanied
by an elevation of the phosphorylation of mitogen-activated
protein kinase MEK1/2 as well as extracellular signal-
regulated kinase [174]. Furthermore, activation of the MT1
receptor also increases potassium conductance by activating
Kir3 (GIRK) inward rectifier potassium channels [175] and po-
tentiates prostaglandin F2a and ATP mediated stimulation of
the activity of protein kinase C (PKC) [176].
Direct free radical scavenging activity of melatonin relates
to its non-receptor mediated actions. Melatonin protects
lipids, proteins and nuclear DNA from oxidative damage
suggests that its intracellular distribution is wide. Electron
donation is the principal mechanism by which melatonin
detoxifies the free radicals [15]. In addition, melatonin
has been reported to neutralize the most toxic oxidizing
agents, hydroxyl radical (OH) and the peroxynitrite anion
(ONOOe), generated within the cells. Moreover, melatonin
reportedly scavenges singlet oxygen (1O2), superoxide anion
radical (O2
e), hydrogen peroxide (H2O2), nitric oxide (NO)
and hypochlorous acid (HClO). Besides this several metabo-
lites of melatonin with high free radical scavenging activity
has been reported to be formed after its interaction with
radicals [40,177,178].14. Conclusion
The practical applicability of melatonin at clinically relevant
concentrations remains unconfirmed in as much as most of
the effects described have not been demonstrated. Moreover,
as a result of pleiotropic nature it may also have side-effects.
For instance, an immunoenhancing substance may not be
beneficial in patients afflicted by an autoimmune disease. On
the other hand, pure preparations of melatonin have usually
been remarkably well tolerated. Therefore it is an important
matter of future research to investigate the clinical efficacy
and safety of melatonin in detail, under different pathological
situations.
In context of this, the present review summarizes all up
to date research of the probable therapeutic functions of
melatonin. Furthermore, its actions as immunoregulatory,
cardioprotectice, hypnotic, bone protective, antiepileptic, an-
tidepressant, oncostatic, antioxidant, neuromodulatory and
chronobiotic molecule have been well explained in literature.
Obviously, while tremendous advances have been made in
establishing melatonin as a beneficial component of optimal
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mechanisms involved.r e f e r e n c e s
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